FindTrial
Sign In

Anti-CCR8 NF mAb

DRUG3 trials

Sponsors

Bristol-Myers Squibb Services Unlimited Company, Humanitas Mirasole S.p.A., Fondazione Humanitas Per La Ricerca Ets

Conditions

Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)MSS)Male and female participants ≥ 18 years of age with advanced or metastatic cancersMetastatic solid tumorsPD-(L)1–refractory/resistant Colorectal cancer (microsatellite stablePD-(L)1–refractory/resistant Gastric adenocarcinomaimmunotherapy‑naïveimmunotherapy‑naïve Pancreatic adenocarcinoma

Phase 1

A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors
RecruitingCTIS2023-503651-10-00
Bristol-Myers Squibb Services Unlimited CompanyMale and female participants ≥ 18 years of age with advanced or metastatic cancers
Start: 2022-05-17Target: 163Updated: 2025-12-04

Phase 2

Immune dynamics and biomarkers of anti-tumor response in BMS-986340 (anti-CCR8) and nivolumab (anti-PD-1) co-treatment of metastatic tumors
Not yet recruitingCTIS2025-524125-40-01
Humanitas Mirasole S.p.A., Fondazione Humanitas Per La Ricerca EtsMetastatic solid tumors, with the following specific indications: Non–Small Cell Lung Cancer (NSCLC), metastatic +5
Target: 30Updated: 2026-07-23
A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitug in Combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as First-line Treatment for Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Not yet recruitingCTIS2026-525170-19-00
Bristol-Myers Squibb Services Unlimited CompanyLocally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Target: 17Updated: 2026-09-07